Fig. 3From: Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021Immunotherapy CSCC-Pathology Results. Three patients who recurred had neither clinical or pathologic response. Two patients who recurred had borderline resectable disease underscoring the importance of patient selectionBack to article page